Tonsillar pseudotumor: Complications of chronically-administered temozolomide

Kathleen Grisdale; Melesa Ritterhouse; Kathy Hunter; Michelle D. Williams; Morris D. Groves

doi:10.1007/s11060-010-0207-8

Tonsillar pseudotumor: Complications of chronically-administered temozolomide

Kathleen Grisdale, Melesa Ritterhouse, Kathy Hunter, Michelle D. Williams, Morris D. Groves

Pathology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M² 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein-Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.

Original language	English (US)
Pages (from-to)	475-479
Number of pages	5
Journal	Journal of neuro-oncology
Volume	100
Issue number	3
DOIs	https://doi.org/10.1007/s11060-010-0207-8
State	Published - Dec 2010

Keywords

Cytomegalovirus
Epstein-Barr Virus
Glioblastoma multiforme
Herpes Simplex Virus
Temozolomide

ASJC Scopus subject areas

Oncology
Neurology
Clinical Neurology
Cancer Research

Access to Document

10.1007/s11060-010-0207-8

Cite this

@article{bc630cc5cdcb4ef39a2451e42fca1b91,

title = "Tonsillar pseudotumor: Complications of chronically-administered temozolomide",

abstract = "The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M2 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein-Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.",

keywords = "Cytomegalovirus, Epstein-Barr Virus, Glioblastoma multiforme, Herpes Simplex Virus, Temozolomide",

author = "Kathleen Grisdale and Melesa Ritterhouse and Kathy Hunter and Williams, {Michelle D.} and Groves, {Morris D.}",

year = "2010",

month = dec,

doi = "10.1007/s11060-010-0207-8",

language = "English (US)",

volume = "100",

pages = "475--479",

journal = "Journal of neuro-oncology",

issn = "0167-594X",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Tonsillar pseudotumor

T2 - Complications of chronically-administered temozolomide

AU - Grisdale, Kathleen

AU - Ritterhouse, Melesa

AU - Hunter, Kathy

AU - Williams, Michelle D.

AU - Groves, Morris D.

PY - 2010/12

Y1 - 2010/12

N2 - The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M2 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein-Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.

AB - The current standard of care for patients with Glioblastoma multiforme (GBM) is surgery, followed by radiation in combination with Temozolomide (TMZ), followed by adjuvant TMZ. The most appropriate length of treatment of adjuvant TMZ after the completion of radiation is unclear. We present the case of a 45 year old female with GBM who received adjuvant TMZ on an experimental study for 24 1-month cycles (150 mg/M2 7 days on/7 days off continuously-a higher TMZ dose than standard). After 24 months on study she was stable without GBM regrowth, but presented with a right tonsil and pharynx mass consistent with a new primary malignancy. Tonsillar biopsy was positive for Epstein-Barr virus, Cytomegalovirus and Herpes Simplex Virus, but no tumor. This case highlights the risks and possible complications of immunosuppression associated with long term TMZ use.

KW - Cytomegalovirus

KW - Epstein-Barr Virus

KW - Glioblastoma multiforme

KW - Herpes Simplex Virus

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=78449295433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449295433&partnerID=8YFLogxK

U2 - 10.1007/s11060-010-0207-8

DO - 10.1007/s11060-010-0207-8

M3 - Article

C2 - 20440539

AN - SCOPUS:78449295433

SN - 0167-594X

VL - 100

SP - 475

EP - 479

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

IS - 3

ER -

Tonsillar pseudotumor: Complications of chronically-administered temozolomide

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this